JB Therapeutics
Newton Center
About JB Therapeutics
JB Therapeutics is a clinical stage biopharmaceutical company developing the first new class of analgesic agents in two decades. Their lead compound, JBT-101, is a potent CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. It has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is currently being developed as a potential disease modifying treatment for osteoarthritis. JBT-101 also represents a platform for combination with other anti-inflammatory and analgesic agents as well as various drug delivery strategies including ointment and gels, topical patches, and timed release formulations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $687.0K
- Funding stage: Seed
- Last round: Seed (Jan 2014)
- Website: jbtherapeutics.com
- Phone: 1-617-413-3020
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/jb-therapeutics-2958110 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.